Mirikizumab
A biologic that blocks the inflammatory protein IL-23.
Also called: omvoh, mirikizamab
Related words interleukin inhibitor biologic
A biologic that blocks the inflammatory protein IL-23.
Also called: omvoh, mirikizamab
Related words interleukin inhibitor biologic
Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.
Sources
NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.
Sources
NICE's appraisal allowing mirikizumab (Omvoh) to be used for adults with moderate to severe Crohn's disease after a previous biologic has not worked or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics Biologics and newer medicines Medicines
Jargon explained IL-23 inhibitor TNF-alpha inhibitor
A guide to mirikizumab (Omvoh), a biologic that blocks the IL-23 protein. It explains the starting doses by drip followed by injections under the skin if it works, vaccine advice, and side effects.
Topics Biologics and newer medicines
Jargon explained IL-23 interleukin inhibitor non-live vaccine
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics Biologics and newer medicines Medicines
Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy
Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.
Topics Biologics and newer medicines
Jargon explained IL-12/23 induction certainty of evidence
A guide to ustekinumab, an interleukin inhibitor that blocks IL-12 and IL-23. Stelara was the first brand and several biosimilars now exist. The first dose is a drip, then injections under the skin; the page covers trial results and side effects.
Topics Biologics and newer medicines
Jargon explained interleukin inhibitor IL-12 IL-23 biosimilar
NICE's appraisal recommending risankizumab (Skyrizi) for people aged 16 and over with moderate to severe Crohn's disease after a previous biologic has failed or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics Biologics and newer medicines Medicines
Jargon explained IL-23 inhibitor TNF-alpha inhibitor biological treatment
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics Biologics and newer medicines Medicines
Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy
NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.
Topics Biologics and newer medicines Medicines
Jargon explained IL-23 inhibitor TNF-alpha inhibitor conventional treatment
A guide to guselkumab (Tremfya), an IL-23 blocking medicine. The first three doses can be a drip or an injection, after which it is injected under the skin; the page covers vaccines and side effects.
Topics Biologics and newer medicines
Jargon explained IL-23 interleukin inhibitor
The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.
Topics Biologics and newer medicines
Jargon explained induction maintenance IL-12/23 placebo
A guide to risankizumab (Skyrizi), a biologic that blocks the IL-23 protein involved in inflammation. You start with a few drips, then have regular injections under the skin; the page explains trial results and side effects.
Topics Biologics and newer medicines
Jargon explained IL-23 interleukin biologic
The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.
Topics Biologics and newer medicines Research
Jargon explained IL-23 maintenance placebo endoscopic response